RA Management: New EULAR Guidelines
- BARCELONA, Spain-The European Alliance of Associations for Rheumatology (EULAR) has issued updated recommendations for treating rheumatoid arthritis (RA).
EULAR has released new guidelines for the management of rheumatoid arthritis (RA), signaling a shift in treatment strategies.The primary focus of these updates centers on the early implementation of biologics or targeted synthetic DMARDs for patients who fail initial methotrexate treatment.These revised recommendations, presented at the EULAR 2025 Annual Meeting, underscore the importance of adapting treatment plans based on individual patient responses. The new guidelines eliminate stratification based on prognostic factors and highlight the continued use of DMARDs, even at lower doses, to maintain remission. Find further insights into the implications of these updated guidelines and how they will influence RA management. News Directory 3 provides comprehensive coverage. Discover what’s next in the evolution of RA treatment.
EULAR Updates Rheumatoid Arthritis Treatment Recommendations
Updated June 20, 2025
BARCELONA, Spain-The European Alliance of Associations for Rheumatology (EULAR) has issued updated recommendations for treating rheumatoid arthritis (RA). The new guidelines advise that patients who do not respond to initial methotrexate therapy should begin treatment with a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD).
The updated recommendations consist of five overarching principles and nine specific recommendations. Josef S.Smolen, MD, of the Medical University of Vienna, presented the revised guidelines at the EULAR 2025 Annual Meeting. He noted the increasing number of effective drugs and clinical trial data